NeoGenomics Inc (NEO)vsNatera Inc (NTRA)
NEO
NeoGenomics Inc
$17.32
-1.65%
HEALTHCARE · Cap: $2.27B
NTRA
Natera Inc
$328.93
+0.86%
HEALTHCARE · Cap: $46.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 253% more annual revenue ($2.71B vs $766.29M). NEO leads profitability with a -6.8% profit margin vs -7.1%. NEO earns a higher WallStSmart Score of 48/100 (D+).
NEO
Hold48
out of 100
Grade: D+
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.2%
Fair Value
$52.45
Current Price
$17.32
$35.13 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
Trading at 25.9x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.2% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Piotroski F-Score, Return on Equity.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
NEO profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.75 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
NEO generates stronger free cash flow (12M), providing more financial flexibility.
Bottom Line
NEO scores higher overall (48/100 vs 31/100) and 11.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?